Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139210

Published: 2020

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Blood (2018) 132 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2018-99-110366

Published: 2018

Journal Articles

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Raphael Itzykson, Nicolas Duployez, Annette Fasan, Gauthier Decool, Alice Marceau-Renaut, Manja Meggendorfer, Eric Jourdan, Arnaud Petit, Hélène Lapillonne, Jean-Baptiste Micol, Pascale Cornillet-Lefebvre, Norbert Ifrah, Guy Leverger, Hervé Dombret, Nicolas Boissel, Torsten Haferlach, Claude Preudhomme

Blood (2018) 132 (2): 187–196.

https://doi.org/10.1182/blood-2018-03-837781

Published: 2018

Includes: Supplemental data

Journal Articles

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Raphael Itzykson, MD PhD, Nicolas Duployez, PharmD, PhD, Annette Fasan, PhD, Alice Marceau-Renaut, PharmD, Manja Meggendorfer, PhD, Eric Jourdan, MD, Arnaud Petit, MD PhD, Hélène Lapillonne, MD PhD, Jean-Baptiste Micol, MD PhD, Pascale Cornillet-Lefebvre, Norbert Ifrah, MD, Guy Leverger, MD PhD, Herve Dombret, MD, Nicolas Boissel, MD PhD, Torsten Haferlach, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 26.

https://doi.org/10.1182/blood.V130.Suppl_1.26.26

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Blood (2017) 130 (Supplement 1): 2587.

https://doi.org/10.1182/blood.V130.Suppl_1.2587.2587

Published: 2017

Journal Articles

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

Blood (2016) 127 (20): 2451–2459.

https://doi.org/10.1182/blood-2015-12-688705

Published: 2016

Includes: Supplemental data

Journal Articles

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, PhD, Pascale Cornillet-Lefebvre, MD, Jacques Delaunay, MD, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, MD, Norbert Ifrah, MD PhD, Hervé Dombret, Claude Preudhomme, Robert K Hills, DPhil, Olivier Hermine

Blood (2015) 126 (23): 1307.

https://doi.org/10.1182/blood.V126.23.1307.1307

Published: 2015

Journal Articles

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Blood (2015) 126 (23): 3736.

https://doi.org/10.1182/blood.V126.23.3736.3736

Published: 2015

Journal Articles

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Blood (2013) 121 (12): 2213–2223.

https://doi.org/10.1182/blood-2012-10-462879

Published: 2013

Includes: Supplemental data

Journal Articles

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Blood (2012) 119 (12): 2943–2948.

https://doi.org/10.1182/blood-2011-05-352989

Published: 2012

Journal Articles

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

Blood (2011) 118 (21): 2608.

https://doi.org/10.1182/blood.V118.21.2608.2608

Published: 2011

Journal Articles

IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias,

Olivier Kosmider, Olivier LaRochelle, Marie-Magdelaine Coude, Veronique Mansat-De Mas, Eric Delabesse, Pascale Cornillet-Lefebvre, Odile Blanchet, Christian Recher, Alain Delmer, MD, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaela Fontenay

Blood (2011) 118 (21): 3556.

https://doi.org/10.1182/blood.V118.21.3556.3556

Published: 2011

Journal Articles

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Blood (2011) 118 (21): 410.

https://doi.org/10.1182/blood.V118.21.410.410

Published: 2011

Journal Articles

Interleukin-10 Promoter Microsatellite Polymorphisms Influence the Immune Response to Heparin and the risk of Heparin-Induced Thrombocytopenia.

Claire Pouplard, PharmD, PhD, Pascale Cornillet-Lefebvre, PharmD, PhD, Redha Attaoua, PharmD, PhD, Dorothee Leroux, PharmD, Florin Grigorescu, MD, PhD, Carinne Lecoq-Lafon, Jerôme Rollin, PhD, Philippe Nguyen, MD, PhD, Yves Gruel, MD

Blood (2010) 116 (21): 3682.

https://doi.org/10.1182/blood.V116.21.3682.3682

Published: 2010

Journal Articles

Are Microarray-Derived Gene Expression Signatures Useful as a Routine Assay for Prognostic Evaluation of Acute Myeloid Leukemia Samples with Low Leukemic Blast Content ?.

Philippe Guardiola, MD, Diane Lambert, PhD, Pascale Cornillet-Lefebvre, MD, PhD, Anne Coutolleau, Laurence Baranger, MD, Franck Genevieve, MD, PhD, Isabelle Luquet, MD, PhD, Annaelle Beucher, Marc Zandecki, PhD, Norbert Ifrah, MD, Odile Blanchet, MD, PhD

Blood (2010) 116 (21): 1658.

https://doi.org/10.1182/blood.V116.21.1658.1658

Published: 2010

Journal Articles

TET2 Mutations in Secondary Acute Myeloid Leukemias: A French Retrospective Study

Olivier Kosmider, Véronique De Mas, Eric Delabesse, Pascale Cornillet-lefevre, Odile Blanchet, Christian Récher, Sophie Raynaud, Catherine Lacombe, Olivier Bernard, Norbert Ifrah, Francois Dreyfus, Michaëla Fontenay on behalf of the GOELAMS

Blood (2010) 116 (21): 176.

https://doi.org/10.1182/blood.V116.21.176.176

Published: 2010

Journal Articles

Trisomy 8 in the Light of Recent Cytogenetic Classification Advances. A Study From the French Acute Myeloid Leukemia Intergroup.

Nicolas Boissel, Christine Terré, Pascale Cornillet-Lefebvre, Odile Maarek, Eric Lippert, Isabelle Tigaud, Nicole Dastugue, Claude Preudhomme, Norbert Ifrah, MD, Hervé Dombret, Isabelle Luquet, MD, PhD

Blood (2009) 114 (22): 2594.

https://doi.org/10.1182/blood.V114.22.2594.2594

Published: 2009

Journal Articles

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Claude Preudhomme, Aline Renneville, Violaine Bourdon, Nathalie Philippe, Catherine Roche-Lestienne, Nicolas Boissel, Nathalie Dhedin, Jean-Marie André, Pascale Cornillet-Lefebvre, André Baruchel, Marie-Joelle Mozziconacci, Hagay Sobol

Blood (2009) 113 (22): 5583–5587.

https://doi.org/10.1182/blood-2008-07-168260

Published: 2009

Includes: Supplemental data

NARROW

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

IDH1/2, TET2 and DNMT3A Mutations Are Not Mutually Exclusive in Secondary Acute Myeloid Leukemias,

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Interleukin-10 Promoter Microsatellite Polymorphisms Influence the Immune Response to Heparin and the risk of Heparin-Induced Thrombocytopenia.

Are Microarray-Derived Gene Expression Signatures Useful as a Routine Assay for Prognostic Evaluation of Acute Myeloid Leukemia Samples with Low Leukemic Blast Content ?.

TET2 Mutations in Secondary Acute Myeloid Leukemias: A French Retrospective Study

Trisomy 8 in the Light of Recent Cytogenetic Classification Advances. A Study From the French Acute Myeloid Leukemia Intergroup.

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only